Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatment options for people with locally advanced or metastatic colorectal cancer mCRC that cannot be removed by surgery and has a specific gene mutation called KRAS G12C. The study aims to evaluate the safety and tolerance of combining calderasib, cetuximab, and mFOLFOX6 chemotherapy compared to the standard treatment of mFOLFOX6 with or without bevacizumab. This research is a phase 3 clinical trial focused on improving outcomes for this specific patient group. Participants will be assigned to one of two groups. One group receives calderasib tablets orally, cetuximab every two weeks, and mFOLFOX6 chemotherapy including oxaliplatin, leucovorin or levofolinate calcium, and 5-fluorouracil every two weeks. The other group receives mFOLFOX6 chemotherapy with or without bevacizumab or a bevacizumab biosimilar, also administered every two weeks. Treatment continues until doctors decide to stop based on specific criteria. During the study, participants will be closely monitored for side effects and treatment tolerability, with evaluations lasting up to about 44 months in the first part and up to 5 years in the second part. Researchers will collect data on progression-free survival, response rates, overall survival, and quality of life using various questionnaires. Safety assessments and tracking of any adverse events will be conducted regularly throughout the study.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of divarasib combined with pembrolizumab compared with pembrolizumab plus pemetrexed and carboplatin or cisplatin for adults with KRAS G12C-mutated, advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have not received prior treatment. This phase 3 randomized study aims to find the best first-line therapy option for this specific lung cancer type. Participants are randomly assigned to one of two groups one group receives divarasib orally once daily and pembrolizumab through intravenous infusion every three weeks, while the other group receives pembrolizumab, pemetrexed, and carboplatin or cisplatin all by intravenous infusion every three weeks. The study treatments are given as first-line therapy, and participants are monitored for up to approximately five years. During the study, participants undergo regular assessments including scans to measure tumor response, evaluations of lung cancer symptoms like cough and breathlessness, quality of life questionnaires, and monitoring for side effects. Researchers track progression-free survival and overall survival for up to about five years. Safety and symptom severity are closely followed throughout the study, providing comprehensive data on treatment impact and participant well-being.
Actively Recruiting
Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.
Actively Recruiting
Non-small cell lung cancer NSCLC is a disease where cancer cells grow uncontrollably in lung tissues. This trial evaluates whether the investigational drug telisotuzumab vedotin works better than docetaxel and assesses its safety in adults with previously treated NSCLC that overexpresses c-Met. The study is a Phase 3 randomized trial involving about 768 participants worldwide to compare disease activity and side effects of these treatments. Participants will be randomly assigned to receive either telisotuzumab vedotin every two weeks or docetaxel every three weeks, both given as intravenous infusions. Treatment continues until specific discontinuation criteria are met. Those who benefit may have the option to continue treatment through an extension or rollover study. The study aims to compare how these two treatments affect disease progression and survival. During the study, participants will have regular hospital or clinic visits for medical assessments, blood tests, side effect monitoring, and questionnaires. Researchers will measure progression-free survival and overall survival up to about 39 months, along with response rates and quality of life indicators. The study includes detailed safety monitoring and may involve a higher treatment burden than standard care.
Actively Recruiting
Researchers are evaluating treatments for adults with multiple myeloma, a type of blood cancer that has returned or is not responding to current therapies. This Phase 2 study focuses on the drug belantamab mafodotin given less frequently alongside standard cancer medicines to see if it can effectively control the disease while reducing side effects, especially those affecting the eyes. The study also monitors overall treatment response and safety. Participants receive belantamab mafodotin combined with one of three standard regimens pomalidomide plus dexamethasone, bortezomib plus dexamethasone, or carfilzomib plus dexamethasone. The drug dosing is extended to potentially reduce side effects. The study is open-label and non-randomized, with each participant assigned to one of these three treatment combinations. During the study, participants undergo regular assessments including eye exams, tests to measure cancer response, and monitoring for side effects. The main outcome measured is the overall response rate up to about 52 months. Secondary measures include complete response rate, minimal residual disease negativity, duration of response, and detailed safety monitoring including eye-related symptoms. The study lasts until August 2030, with ongoing safety and effectiveness evaluations throughout.
Actively Recruiting
Researchers are investigating the efficacy of divarasib compared with the investigators choice of immunotherapy pembrolizumab or nivolumab or observation in adults with resected Stage II-IIIB non-small cell lung cancer NSCLC that tests positive for the KRAS G12C mutation. This study focuses on participants who have not achieved a complete pathological response following neoadjuvant chemoimmunotherapy, regardless of tumor PD-L1 status. The trial aims to assess disease-free survival and overall survival in this patient group. Participants will be randomly assigned to one of two groups. One group will receive divarasib orally once daily for up to 52 cycles, each cycle lasting 21 days. The other group will receive either pembrolizumab or nivolumab immunotherapy, administered according to prior treatment type, or will be observed without study treatment. Pembrolizumab is given as an intravenous infusion every three weeks or a subcutaneous injection every three weeks for up to 13 cycles. Nivolumab is given as an intravenous infusion or subcutaneous injection every four weeks for up to 13 cycles. Observation participants will not receive any study treatment. Throughout the study, participants will be monitored for disease recurrence or death for up to approximately five years to assess disease-free survival. Additional outcomes include overall survival for up to eight years, adverse events tracking up to 60 days after treatment ends, and disease-free survival rates at two and three years. Participants will undergo regular evaluations to monitor their health status and study outcomes. The total duration of participation may extend up to eight years from randomization.
Actively Recruiting
This trial focuses on premenopausal women aged 18 to 55 with hormone receptor-positive breast cancer, either early-stage or advanced. Researchers are evaluating how well ZOLADEX 10.8 mg suppresses ovarian function by measuring luteinizing hormone LH levels. The study aims to assess the consistency and degree of ovarian suppression achieved with this treatment. Participants receive two doses of ZOLADEX 10.8 mg as subcutaneous injections, administered on Day 1 and Day 85. The trial includes two parallel groups based on breast cancer stage, with treatment effects monitored over several weeks. The study is open-label, meaning both participants and researchers know the treatment being given. Throughout the study, participants undergo regular assessments of LH, estradiol levels, and menstrual status at weeks 6, 12, 18, and 24. These evaluations help determine how effectively ovarian suppression is maintained. Safety and adherence are monitored, with the primary outcome focused on LH values below a specific threshold at week 6. The total participation lasts at least 24 weeks, with follow-up visits to track hormonal changes and menstrual status.
Actively Recruiting
Researchers are evaluating how effective trastuzumab deruxtecan T-DXd is for patients in the US with HER2-positive IHC 3 solid tumors that are locally advanced, cannot be removed by surgery, or have spread to other parts of the body. These patients have already received prior systemic treatments for advanced disease and currently have no satisfactory treatment options. The study focuses on a real-world setting to better understand treatment outcomes outside of controlled clinical trials. This is a multicenter, hybrid observational study involving about 100 patients who start T-DXd treatment as part of their routine care following FDA guidelines. Patients with certain cancers like breast, colorectal, non-small cell lung, gastricgastroesophageal junction cancers, or blood cancers are not included. The study takes place at approximately 30 sites including community practices, hospitals, and academic centers to reflect typical care environments. Participants will be observed from the start of their T-DXd treatment with data collected on their response to therapy, how long the response lasts, time until treatment stops, and time until the next treatment begins. These outcomes will be tracked for up to 2.5 years after enrollment. No additional interventions are given beyond usual care, and patients will provide informed consent before joining the study.
Actively Recruiting
Researchers are collecting clinical data and biological samples from adults diagnosed with stage I, stage II, or operable stage III cancers in certain solid tumor types. This observational study aims to help develop tests that improve cancer detection and assess the risk of cancer returning. Participants continue to receive standard care from their own doctors throughout the study. Participants will provide blood and tumor tissue samples during their routine care. The study includes several tumor groups such as bladder cancer, esophageal cancer, gastric and gastroesophageal junction cancer, melanoma, non-small cell lung cancer, pancreatic cancer, and a mix of other solid tumors. Enrollment occurs either before or within three months after surgery, and no prior systemic therapy for the current cancer is allowed before joining. During the approximately five and a half years of involvement, participants will be observed with collection of blood and tissue samples as part of a biospecimen registry. Researchers will use this information to study molecular residual disease in solid tumors. All clinical data and samples will be gathered under routine care settings, with no additional treatment provided by the study team.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of sacituzumab govitecan-hziy SG combined with pembrolizumab compared to treatment chosen by a physician for people with triple negative breast cancer that remains after surgery and pre-surgical treatment. This phase 3 trial focuses on participants whose cancer has not been fully eliminated by prior therapies and aims to find if the experimental combination improves invasive disease-free survival. Participants are randomly assigned to one of two groups. One group receives SG intravenously at 10 mgkg on Days 1 and 8 of each 21-day cycle plus pembrolizumab 200 mg intravenously on Day 1 of each cycle for up to 8 cycles. The other group receives either pembrolizumab alone or pembrolizumab plus oral capecitabine as determined before randomization, also for up to 8 cycles. Treatment continues until reaching 8 cycles, disease recurrence, unacceptable side effects, physician decision, consent withdrawal, or death. During the study, participants undergo various evaluations including monitoring for invasive disease-free survival for up to 60 months and overall survival for up to 96 months. Researchers also track recurrence-free survival, distant disease-free survival, treatment side effects, laboratory abnormalities, and quality of life changes. Safety assessments occur up to 38 months after the first dose plus 30 days. This long-term follow-up helps understand the treatments impact over several years.